| Literature DB >> 22316387 |
Sheng Pan1, Ru Chen, Randall E Brand, Sarah Hawley, Yasuko Tamura, Philip R Gafken, Brian P Milless, David R Goodlett, John Rush, Teresa A Brentnall.
Abstract
Biomarkers are most frequently proteins that are measured in the blood. Their development largely relies on antibody creation to test the protein candidate performance in blood samples of diseased versus nondiseased patients. The creation of such antibody assays has been a bottleneck in biomarker progress due to the cost, extensive time, and effort required to complete the task. Targeted proteomics is an emerging technology that is playing an increasingly important role to facilitate disease biomarker development. In this study, we applied a SRM-based targeted proteomics platform to directly detect candidate biomarker proteins in plasma to evaluate their clinical utility for pancreatic cancer detection. The characterization of these protein candidates used a clinically well-characterized cohort that included plasma samples from patients with pancreatic cancer, chronic pancreatitis, and healthy age-matched controls. Three of the five candidate proteins, including gelsolin, lumican, and tissue inhibitor of metalloproteinase 1, demonstrated an AUC value greater than 0.75 in distinguishing pancreatic cancer from the controls. In addition, we provide an analysis of the reproducibility, accuracy, and robustness of the SRM-based proteomics platform. This information addresses important technical issues that could aid in the adoption of the targeted proteomics platform for practical clinical utility.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22316387 PMCID： PMC3292708 DOI： 10.1021/pr201117w
Source DB: PubMed Journal: J Proteome Res ISSN： 1535-3893 Impact factor: 4.466